Forian Overview
Latest ROE for Forian: -18.15% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-18.15%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Forian (FORA) currently reports a ROE of -18.15%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Forian's ROE history and peer comparisons.
Forian's ROE of -18.15% is lower than the Healthcare sector average of 21.28%. That is roughly 185.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Forian's current -18.15% should be judged against Healthcare norms (sector average: 21.28%) and against FORA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -18.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Forian, and consider following FORA for alerts when major investors trade the stock.
Forian is classified in the Healthcare sector. On ROE, it currently shows -18.15% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FORA with unrelated industries.
